Abstract
The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia’s longest serving medical research institute. WEHI’s High Throughput Screening (HTS) Facility was established in 2003 with $5 million of infrastructure funds invested by WEHI, and the Victorian State Government’s Strategic Technology Initiative through Bio21 Australia Ltd. The Facility was Australia’s first truly academic HTS facility and was one of only a handful operating in publicly funded institutions worldwide at that time. The objectives were to provide access to enabling HTS technologies, such as assay design, liquid handling automation, compound libraries and expertise to promote translation of basic research in a national setting that has a relatively young biotech sector and does not have a big Pharma research presence. Ten years on and the WEHI HTS Facility has participated in over 92 collaborative projects, generated over 18 million data points, and most importantly, projects that began in the Facility have been commercialized successfully (due to strong ties with Business Development and emphasis on intellectual property management) and now have molecules progressing in clinical trials.
Keywords: Academic, cancer, chemical libraries, HTS, malaria, therapeutics, trypanosomiasis.
Combinatorial Chemistry & High Throughput Screening
Title:A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research – Eighteen Million Assays and Counting
Volume: 17 Issue: 3
Author(s): Kurt Lackovic, Guillaume Lessene, Hendrik Falk, Karl-Johan Leuchowius, Jonathan Baell and Ian Street
Affiliation:
Keywords: Academic, cancer, chemical libraries, HTS, malaria, therapeutics, trypanosomiasis.
Abstract: The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia’s longest serving medical research institute. WEHI’s High Throughput Screening (HTS) Facility was established in 2003 with $5 million of infrastructure funds invested by WEHI, and the Victorian State Government’s Strategic Technology Initiative through Bio21 Australia Ltd. The Facility was Australia’s first truly academic HTS facility and was one of only a handful operating in publicly funded institutions worldwide at that time. The objectives were to provide access to enabling HTS technologies, such as assay design, liquid handling automation, compound libraries and expertise to promote translation of basic research in a national setting that has a relatively young biotech sector and does not have a big Pharma research presence. Ten years on and the WEHI HTS Facility has participated in over 92 collaborative projects, generated over 18 million data points, and most importantly, projects that began in the Facility have been commercialized successfully (due to strong ties with Business Development and emphasis on intellectual property management) and now have molecules progressing in clinical trials.
Export Options
About this article
Cite this article as:
Lackovic Kurt, Lessene Guillaume, Falk Hendrik, Leuchowius Karl-Johan, Baell Jonathan and Street Ian, A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research – Eighteen Million Assays and Counting, Combinatorial Chemistry & High Throughput Screening 2014; 17 (3) . https://dx.doi.org/10.2174/1386207317666140109122450
DOI https://dx.doi.org/10.2174/1386207317666140109122450 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Eco-friendly Agents for Biological Control of Pathogenic Diseases
The discovery of an alternative biological approach to disease management includes work on medicinal products derived from natural sources as a starting point for the development of eco-friendly agents for these diseases and the injuries they cause, as well as reducing human contact with hazardous chemicals and their residues. We ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Nucleoprotein-Derived and Unbound Ribonucleosides: Bioactivity and Potential Applications
Current Pharmaceutical Design Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Regulation of MMPs During Melanoma Progression: From Genetic to Epigenetic
Anti-Cancer Agents in Medicinal Chemistry Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Monitoring and Surveillance of Obesity in the United States
Current Nutrition & Food Science Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery
Current Pharmaceutical Design Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome
Current Molecular Medicine Towards a Stratified Targeted Approach with Biologic Treatments in Rheumatoid Arthritis: Role of Synovial Pathobiology
Current Pharmaceutical Design Preclinical Toxicity of Paclitaxel Biopolymer Formulation
Anti-Cancer Agents in Medicinal Chemistry Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Current Cancer Drug Targets Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Current Cancer Drug Targets Pentoxifylline Use in Dermatology
Inflammation & Allergy - Drug Targets (Discontinued)